Clinical Trial

A Study to Investigate Efficacy and Safety of FWY003 Compared With Placebo in Participants With Geographic Atrophy Secondary to Age-related Macular Degeneration

Recruiting Phase 2
View on ClinicalTrials.gov →
Summary
To characterize the dose response relationship of FWY003 in participants with geographic atrophy (GA) secondary to age-related macular degeneration (AMD).
Protocol Amendment History 8 changes
notable Trial sites expanded: 41 -> 51 locations 2026-07-10
notable Trial sites expanded: 38 -> 41 locations 2026-06-27
notable Trial sites expanded: 35 -> 38 locations 2026-06-24
notable Trial sites expanded: 28 -> 35 locations 2026-06-19
notable Trial sites expanded: 22 -> 28 locations 2026-06-06
notable Trial sites expanded: 19 -> 22 locations 2026-06-02
notable Trial sites expanded: 16 -> 19 locations 2026-05-28
notable Trial sites expanded: 7 -> 12 locations 2026-05-05
Trial Details
NCT Number NCT07441642
Lead Sponsor Novartis Pharmaceuticals
Conditions Geographic Atrophy Secondary to Age-related Macular Degeneration
Enrollment 272 participants
Start Date 2026-03-09
Primary Completion 2029-08-21 (estimated)
Study Completion 2029-08-22 (estimated)
Updated on ClinicalTrials.gov 2026-07-09